ORIC Pharmaceuticals

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing therapies that address cancer resistance mechanisms. Their lead product candidates include enozertinib (ORIC-114), an irreversible inhibitor targeting EGFR and HER2 exon 20 mutations, and rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer. The company's mission is to improve patients' lives by overcoming resistance in cancer treatments.